Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, with co-primary endpoints of 14 days…

Read More

Top Global Pharmaceutical Firms Pledge Quality Healthcare For 1.7 Million Africans

JOHNSON &JOHNSON together with other major global pharmaceutical players have joined hands with Last Mile Health and Living Goods to increase access to healthcare to community based primary healthcare for nearly 1.7 million people in not less than six African countries. HealthTimes Repoter The other firms include  Lilly, Novartis (Novartis.com), Pfizer (Pfizer.com), GSK (GSK.com) and the Bill & Melinda Gates Foundation (GatesFoundation.org) and the pledge is part of their shared commitment to accelerate universal health coverage. The Health Worker Training Initiative is a three-year investment, generously matched by The Audacious…

Read More